22 Oct 2009: Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim. The collaboration, which was initiated in August 2004, has up to now resulted in seven milestone payments. The achievement of the current milestone has led to a payment to Evotec of €2.5 million. The milestone was achieved
for the selection of a candidate compound for pre-development studies in a cardiometabolic programme.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are extremely pleased that we have achieved another milestone in our alliance with Boehringer Ingelheim. This is the second milestone that we have achieved in 2009 and further demonstrates the success of our collaboration. We are looking forward to continuing our collaboration into 2010 and beyond and achieving further milestones as we progress several projects towards the clinic.”